<DOC>
	<DOC>NCT00566241</DOC>
	<brief_summary>28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and composition in adults with cystic fibrosis.</brief_summary>
	<brief_title>IGF-1 Therapy in Patients With Cystic Fibrosis</brief_title>
	<detailed_description>28 week, double blind, cross over study to determine the efficacy of rhIGF-1 on body weight and body composition in patients with cystic fibrosis.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Diagnosis of cystic fibrosis as proven by either sweat chloride or DNA analysis. Age &gt;= 18 yr. Tanner stage: Femake Breasts: 45 Male Genitalia: 45 Exclusion criteria: Hemoglobin A1C &gt; 8.5 % Diabetic retinopathy Obstructive sleep apnea Respiratory failure requiring mechanical ventilation. Status post pulmonary transplantation. Concurrent or recent (within past 6 months) receipt of human growth hormone. History of adverse side effects to growth hormone other than carbohydrate intolerance. Pregnancy or attempting pregnancy. Women who are breast feeding. Sexually active women who refuse to use or are incapable of responsibly using reliable contraception. Proven non compliance with medical regimens. Inability or refusal to take subcutaneous injections. Known allergy to components in the IGFI preparation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Body weight</keyword>
	<keyword>Body composition</keyword>
	<keyword>Pulmonary function</keyword>
	<keyword>Carbohydrate tolerance</keyword>
</DOC>